Not just As­traZeneca — CanSi­no Bi­o­log­ics al­so un­veils Phase II da­ta, show­ing an­ti­body and T cell re­sponse

The biotech and in­fec­tious dis­ease world — much of the world, re­al­ly — sat ea­ger­ly an­tic­i­pat­ing the ear­ly Covid-19 vac­cine da­ta As­traZeneca and the Lancet had promised would emerge on Mon­day. Then, at 9:30 EST, the Lancet post­ed not on­ly the As­traZeneca da­ta but a sec­ond batch of im­por­tant re­sults: the Phase II da­ta from Chi­nese biotech CanSi­no Bi­o­log­ics.

As­traZeneca, Mod­er­na and Pfiz­er, among oth­ers, have cap­tured much of the at­ten­tion in Eu­rope and North Amer­i­ca, where coun­tries have helped ush­er the vac­cines through tri­als and signed deals for hun­dreds of mil­lions of dos­es. But CanSi­no was the first of any ef­fort to re­port Phase I da­ta and they’ve rolled along at the front of the pack since.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER